Search
Biogen Inc
BIIBAdd to Watchlist
218.120USD
+1.340+0.62%
Close 08-24 16:00（ET）
32.19BMarket Cap
23.33P/E TTM
Forecast
Currency: USD Updated: 2026-08-21The current earnings forecast score of Biogen Inc is 7.62, ranking 99 out of 155 in the Pharmaceuticals industry. The average price target is 171.00, with a high of 260.00 and a low of 130.00.
Analyst Rating
Based on
37
analysts
Buy
Current Rating
235.781
Target Price
+8.77%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Biogen Inc
BIIB
37
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Regeneron Pharmaceuticals Inc
REGN
30
Alnylam Pharmaceuticals Inc
ALNY
30
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Biogen Inc's expected revenue for the next quarter?
Biogen Inc's expected revenue is 2.64B.
What is Biogen Inc's price target?
Analysts forecast that Biogen Inc's price target is USD 171.00, with the highest forecast at USD 260.00 and the lowest forecast at USD 130.00.
How have Biogen IncBIIB's recent earnings per share performed?
The market expectation was USD 0.66, while Biogen IncBIIB's earnings per share (EPS) for the previous quarter was USD 2.17. EPS for the next quarter is expected at USD 2.03.
What is the analyst rating for Biogen Inc?
Based on the ratings of Biogen Inc's stock from 37 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.